Mural Oncology plc is a biotechnology company focused on advancing innovative treatments for cancer. The company is dedicated to developing novel therapeutic approaches by harnessing the power of immunotherapy and targeted drug delivery to improve patient outcomes. Mural Oncology aims to address significant unmet medical needs in oncology by creating treatments that enhance the body’s natural immune response and effectively target cancer cells. Through rigorous research and development, the company strives to bring transformative solutions to the market that can change the landscape of cancer therapy. Read More
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Mural Oncology plc (NASDAQ: MURA) to XOMA Royalty Corporation for $2.035 per share and, up to an additional $0.205 per share under certain conditions, is fair to Mural shareholders.
As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Shares of Mural Oncology plc (NASDAQ: MURA) are soaring Monday following the company's announcement that it will discontinue clinical development of its lead drug candidate Nemvaleukin and begin exploring strategic alternatives.
Following review of data from the phase 2 ARTISTRY-6 trial and previously announced results from the phase 3 ARTISTRY-7 trial, Mural will discontinue all clinical development of nemvaleukin
